The Filing Desk

Aytu Biopharma vs Nektar Therapeutics

Aytu Biopharma AYTU · Nektar Therapeutics NKTR · Pharmaceuticals

Aytu Biopharma reported revenue of $58 million in fiscal 2026, about the same as Nektar Therapeutics' $55 million in fiscal 2025. Aytu Biopharma's revenue fell 13.3% in its latest year, and Nektar Therapeutics' fell 43.9%. Aytu Biopharma had an operating margin of -14.4%, against -253.7% at Nektar Therapeutics. Free cash flow was $3 million at Aytu Biopharma and −$209 million at Nektar Therapeutics. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.

Side by side

Aytu BiopharmaNektar Therapeutics
Latest fiscal yearFY2026, Jun 30, 2026FY2025, Dec 31, 2025
Revenue$58M$55M
Revenue growth−13.3%−43.9%
Revenue growth a year, last 5 years−2.6%−18.4%
Gross margin64.0%100.0%
Operating margin−14.4%−253.7%
Net margin−24.8%−297.1%
Free cash flow$3M−$209M
Free cash flow margin5.7%−377.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count96.2%23.1%
Last close$2.66$32.54
P/E at the last close——
Insider trades, last 12 months—sold $2.5 million
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aytu BiopharmaNektar Therapeutics
Operating margin
Percent of revenue
Aytu BiopharmaNektar Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aytu BiopharmaNektar Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aytu Biopharma and Nektar Therapeutics pages.